PEDIATRICS Vol. 77 No. 6 June 1986, pp. 912-915
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Martinez-Roíg, A.
Right arrow Articles by Perich, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martinez-Roíg, A.
Right arrow Articles by Perich, F.

Acetylation Phenotype and Hepatotoxicity in the Treatment of Tuberculosis in Children

A. Martinez-Roíg MD1, J. Camí MD, PhD1, J. Llorens-Terol MD1, R. de la Torre PhD1, and F. Perich PhD1

1 From the Department of Pediatrics and Clinical Pharmacology, Hospital Nuestra Señora del Mar, Universitat Autónoma de Barcelona, Barcelona, Spain

We studied the relationship between acetylation phenotype and the appearance of biochemical and clinical signs of liver damage in 73 tuberculous children treated with isoniazid and rifampin. No significant differences were found with respect to the distribution of acetylation phenotype between tuberculous patients and a control group consisting of 256 children. Hepatotoxicity manifested in 27 cases (37%), of which only five (7%) had clinical signs. Application of the Fisher exact probability test did not show a relationship between acetylation phenotype and hepatotoxicity.

Key Words: acetylation • hepatotoxicity • liver function test • tuberculosis • isoniazid

Submitted on April 1, 1985
Accepted on October 9, 1985




This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
J. J. Saukkonen, D. L. Cohn, R. M. Jasmer, S. Schenker, J. A. Jereb, C. M. Nolan, C. A. Peloquin, F. M. Gordin, D. Nunes, D. B. Strader, et al.
An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy.
Am. J. Respir. Crit. Care Med., October 15, 2006; 174(8): 935 - 952.
[Abstract] [Full Text] [PDF]